中国医院用药评价与分析2023，Vol.23Issue(12)：1454-1457,4.DOI:10.14009/j.issn.1672-2124.2023.12.009
帕博利珠单抗联合阿帕替尼对晚期胃癌化疗患者疾病缓解率及生存情况的影响
Effects of pabolizumab Combined with Apatinib on Remission Rate and Survival in Patients with Advanced Gastric Cancer Undergoing Chemotherapy
摘要
Abstract
OBJECTIVE:To observe the effects of pabolizumab combined with apatinib on remission rate and survival in patients with advanced gastric cancer undergoing chemotherapy,and to probe into the selection of treatment for advanced gastric cancer.METHODS:Clinical data of 107 patients with advanced gastric cancer admitted into Hainan West Central Hospital from Aug.2018 to Jan.2021 were retrospectively analyzed.All patients were divided into 52 cases in the observation group(pabolizumab + apatinib + chemotherapy)and 55 cases in the control group(chemotherapy alone + apatinib)according to different treatment regimens.The objective response rate(ORR)of two groups at 3 cycles of treatment was calculated.With Jan.31st,2023 as the follow-up end point,the overall survival(OS)and progression-free survival(PFS)of two groups were calculated,and the adverse reactions of two groups during treatment was recorded.RESULTS:The ORR of observation group was 59.62%(31/52),higher than 36.36%(20/55)of the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in disease control rate between two groups(P>0.05).The OS and PFS in the observation group were longer than those in the control group,with statistically significant difference(P<0.05).The incidence of digestive tract reaction in the observation group was higher than that in the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of other adverse reactions between two groups(P>0.05).CONCLUSIONS:Pabolizumab combined with apatinib as the third line treatment regimens can improve the disease remission rate of patients with advanced gastric cancer undergoing chemotherapy,prolong the survival time of patients.Prolonged application may have some effect on patients'digestive function,yet does not increase the occurrence of other adverse reactions.关键词
晚期胃癌/帕博利珠单抗/阿帕替尼/疾病缓解率/生存时间Key words
Advanced gastric cancer/Pabolizumab/Apatinib/Disease remission rate/Survival time分类
药学引用本文复制引用
林锋,黎爱,何丽云,黄建鹏..帕博利珠单抗联合阿帕替尼对晚期胃癌化疗患者疾病缓解率及生存情况的影响[J].中国医院用药评价与分析,2023,23(12):1454-1457,4.基金项目
海南省卫生计生行业科研项目(No.18A200148) （No.18A200148）
